Hagens Berman has opened an investigation into CVRx Inc. (NASDAQ: CVRX) regarding potential violations of federal securities laws. The inquiry follows a 59% decline in the company's stock price on August 7, 2026, triggered by disclosures of a U.S. Department of Justice Civil Investigative Demand and severe operational setbacks.

The litigation firm is examining whether CVRx misled investors about the state of its commercial sales force and Medicare Advantage reimbursement rates. The investigation also seeks to determine if there is a direct connection between the Department of Justice demand and the abrupt termination of Chief Revenue Officer Robert John on August 10, 2026.

Operational and legal headwinds

CVRx’s sole commercial product, Barostim, is an FDA-approved implantable neuromodulation device for heart failure patients. Historically, the company assured investors that its growth strategy relied on a completed sales force transformation and high approval rates from Medicare Advantage payers. CVRx had repeatedly highlighted a $10.5 billion market opportunity with less than 1% penetration.

However, after market close on August 6, 2026, the company disclosed significant issues:

• DOJ Civil Investigative Demand: Received on May 14, 2026, investigating whether CVRx caused false claims submissions to government health programs through improper marketing or kickbacks.
• Sales Force Deterioration: The company cut its 2026 revenue expectations, citing sequentially flat growth in sales territories, high turnover, and strained onboarding.
• Reimbursement Collapse: A primary Medicare Advantage payer increased initial denials, reducing 30-day approvals to 25% from a historical 80%.

What the numbers show

The divergence between CVRx’s prior assurances and its August disclosures highlights a critical dependency risk. The company previously marketed its sales force transformation as "largely complete" while relying heavily on a single Medicare Advantage payer that historically approved 80% of prior authorizations within 30 days. The sudden drop in approvals to 25% directly contradicts the stability implied by the earlier claims, suggesting that the reported market penetration potential was contingent on reimbursement conditions that deteriorated rapidly.

Investor recourse

Hagens Berman partner Reed Kathrein stated the firm is investigating whether there is a direct connection between the Department of Justice demand and the immediate termination of the Chief Revenue Officer. Investors who suffered substantial losses are encouraged to contact the firm to evaluate their legal rights. Whistleblowers with non-public information may also participate in the SEC Whistleblower program, which offers rewards of up to 30% of successful recoveries.

CVRx, Inc. (NASDAQ: CVRX) has appointed John Landry as its new Chief Financial Officer. Landry will join the commercial-stage medical device company on October 12, 2026, succeeding Jared Oasheim.

Landry assumes the CFO role the day after the company files its Form 10-Q for the quarter ending September 30, 2026. Oasheim will remain with CVRx during a transition period consistent with his previously disclosed agreement.

Leadership Transition

Kevin Hykes, President and CEO of CVRx, stated that Landry brings significant commercial and capital markets experience. Hykes noted that Landry’s background in driving growth while managing expenses is relevant as CVRx scales its Barostim therapy for heart failure patients.

Hykes thanked Oasheim for his contributions since 2015, highlighting his role in leading the company through its initial public offering and building its financial foundation.

Candidate Profile

Landry currently serves as CFO of Nyxoah SA (Euronext Brussels/NASDAQ: NYXH). In that role, he raised several rounds of capital and drove operational efficiencies to fund U.S. commercial expansion.

Prior to Nyxoah, Landry spent 12 years at Vapotherm, Inc. (NYSE: VAPO), most recently as Senior Vice President and CFO. He led Vapotherm’s IPO and built its finance, investor relations, and public company reporting functions. Earlier roles include positions at Salient Surgical Technologies, Bottomline Technologies, Hussey Seating Company, and Coopers & Lybrand.

Landry holds a B.S. in Accountancy from Bentley College, is an inactive CPA, and serves on the board of Liberate Medical, Inc.

Strategic Focus

Landry cited the positive impact of Barostim on patients’ lives as a key draw for the role. Barostim is the first FDA-approved medical technology using neuromodulation to improve symptoms in heart failure patients. It delivers electrical pulses to baroreceptors in the carotid artery wall to restore autonomic nervous system balance.

The device holds FDA Breakthrough Device designation and CE Mark approval for heart failure and resistant hypertension in the European Economic Area.